Microdose flare protocol with interrupted follicle stimulating hormone and added androgen for poor responders—an observational pilot study  Frederic Mitri,

Slides:



Advertisements
Similar presentations
Lisa Marii Cookingham, M. D. , Rachel P. Goossen, B. A. , Amy E. T
Advertisements

The effectiveness of gonadotropin-releasing hormone antagonist in poor ovarian responders undergoing in vitro fertilization: a systematic review and meta-analysis 
Direct vitamin D3 actions on rhesus macaque follicles in three-dimensional culture: assessment of follicle survival, growth, steroid, and antimüllerian.
Diminished ovarian reserve as measured by means of baseline follicle-stimulating hormone and antral follicle count is not associated with pregnancy loss.
Quality of life and psychosocial and physical well-being among 1,023 women during their first assisted reproductive technology treatment: secondary outcome.
Yuqian Cui, M. D. , Ph. D. , Yuhua Shi, M. D. , Ph. D. , Linlin Cui, M
A giant oocyte in a cohort of retrieved oocytes: does it have any effect on the in vitro fertilization cycle outcome?  Ronit Machtinger, M.D., Joseph.
Luteal-phase ovarian stimulation is feasible for producing competent oocytes in women undergoing in vitro fertilization/intracytoplasmic sperm injection.
Safety and feasibility of performing two consecutive ovarian stimulation cycles with the use of letrozole-gonadotropin protocol for fertility preservation.
Edward G. Hughes, M.B., F.R.C.S.(C.), Deirdre DeJean, M.Sc. 
The aging oocyte—can mitochondrial function be improved?
Mike Ripley, M. D. , F. R. C. S. C. , Andrea Lanes, M. Sc
Administration of a gonadotropin-releasing hormone antagonist during the 3 days before the initiation of the in vitro fertilization/intracytoplasmic sperm.
Patient-tailored ovarian stimulation for in vitro fertilization
Impact of final oocyte maturation using gonadotropin-releasing hormone agonist triggering and different luteal support protocols on endometrial gene expression 
Cem Atabekoglu, M. D. , Murat Sonmezer, M. D. , Sinan Özkavukcu, M. D
Antimüllerian hormone levels and antral follicle count as prognostic indicators in a personalized prediction model of live birth  Scott M. Nelson, M.R.C.O.G.,
Follicle-stimulating hormone administered at the time of human chorionic gonadotropin trigger improves oocyte developmental competence in in vitro fertilization.
The role of antimullerian hormone in prediction of outcome after IVF: comparison with the antral follicle count  Simone L. Broer, B.Sc., Ben Willem J.
Hakan Cakmak, M. D. , Audra Katz, R. N. , Marcelle I. Cedars, M. D
Grant D.E. McWilliams, D.O., John L. Frattarelli, M.D. 
How old is too old? Challenges faced by clinicians concerning age cutoffs for patients undergoing in vitro fertilization  Robert L. Klitzman, M.D.  Fertility.
Potential diagnostic utility of intermittent administration of short-acting gonadotropin- releasing hormone agonist in gonadotropin deficiency  Carrie.
Randomized, controlled pilot trial of natural versus hormone replacement therapy cycles in frozen embryo replacement in vitro fertilization  Ginny Mounce,
Reproductive aging and variability in the ovarian antral follicle count: application in the clinical setting  Karl R Hansen, M.D., Ph.D., Jamie L Morris,
Diminished ovarian reserve as measured by means of baseline follicle-stimulating hormone and antral follicle count is not associated with pregnancy loss.
Improved monofollicular ovulation in anovulatory or oligo-ovulatory women after a low- dose step-up protocol with weekly increments of 25 international.
Oocyte cryopreservation
Evaluating the performance of serum antimullerian hormone concentration in predicting the live birth rate of controlled ovarian stimulation and intrauterine.
Modification of the Beckman-Coulter second-generation enzyme-linked immunosorbent assay protocol improves the reliability of serum antimüllerian hormone.
Lisa Marii Cookingham, M. D. , Rachel P. Goossen, B. A. , Amy E. T
Robert F. Casper, M.D.  Fertility and Sterility 
Xiuye Xing, M. D. , Ph. D. , Han Zhao, M. D. , Ph. D. , Mei Li, M. Sc
Ultrashort flare gonadotropin-releasing hormone (GnRH) agonist/GnRH antagonist protocol: a valuable tool in the armamentarium of ovulation induction for.
Comparison of luteal estradiol patch and gonadotropin-releasing hormone antagonist suppression protocol before gonadotropin stimulation versus microdose.
René Ecochard, M. D. Ph. D. , Agnes Guillerm, M. D. , René Leiva, M. D
The effectiveness of gonadotropin-releasing hormone antagonist in poor ovarian responders undergoing in vitro fertilization: a systematic review and meta-analysis 
Duphaston and human menopausal gonadotropin protocol in normally ovulatory women undergoing controlled ovarian hyperstimulation during in vitro fertilization/intracytoplasmic.
Does stimulation with human gonadotropins and gonadotropin-releasing hormone agonist enhance and accelerate the developmental capacity of oocytes in human.
Impact of pituitary suppression on antral follicle count and oocyte recovery after ovarian stimulation  Nam D. Tran, M.D., Ph.D., Lusine Aghajanova, M.D.,
Tomer Singer, M. D. , David H. Barad, M. D. , M. S
Comparison of antimüllerian hormone levels and antral follicle count as predictor of ovarian response to controlled ovarian stimulation in good-prognosis.
Stephanie L. F. Gustin, M. D. , Gourab Mukherjee, Valerie L. Baker, M
Clinical and endocrine response to the withdrawal of gonadotropin-releasing hormone agonists during prolonged coasting  Basil Ho Yuen, M.B., Ch.B., Tuan-Anh.
Efficacy and safety of human chorionic gonadotropin for follicular phase stimulation in assisted reproduction: a systematic review and meta-analysis 
Prospective cohort study of three- versus two-dimensional ultrasound for prediction of oocyte maturity  Doron Shmorgun, M.D., Edward Hughes, M.D., Patrick.
Fertility and Sterility
Effectiveness of highly purified human menopausal gonadotropin vs
Nulliparity, fertility treatments and twins: a time for rethinking
Antimüllerian hormone in gonadotropin releasing-hormone antagonist cycles: prediction of ovarian response and cumulative treatment outcome in good-prognosis.
The serum follicle-stimulating hormone-to-luteinizing hormone ratio at the start of stimulation with gonadotropins after pituitary down-regulation is.
Antral follicle counts are strongly associated with live-birth rates after assisted reproduction, with superior treatment outcome in women with polycystic.
Moderately elevated levels of basal follicle-stimulating hormone in young patients predict low ovarian response, but should not be used to disqualify.
Follicular phase serum levels of luteinizing hormone do not influence delivery rates in in vitro fertilization cycles down-regulated with a gonadotropin-releasing.
Impact of subclinical hypothyroidism in women with recurrent early pregnancy loss  Lia A. Bernardi, M.D., Ronald N. Cohen, M.D., Mary D. Stephenson, M.D.,
Use of Utrogestan during controlled ovarian hyperstimulation in normally ovulating women undergoing in vitro fertilization or intracytoplasmic sperm injection.
Effects of gonadotropin-releasing hormone agonist/recombinant follicle-stimulating hormone versus gonadotropin-releasing hormone antagonist/recombinant.
Genetic evaluation procedures at sperm banks in the United States
A woman with premature ovarian failure induced by Tripterygium wilfordii Hook.f. gives birth to a healthy child  Xin Chen, M.D., M.Sc., Shi-ling Chen,
Fertility and Sterility
David H. Barad, M.D., M.S., Norbert Gleicher, M.D. 
Comparing anti-Müllerian hormone (AMH) and follicle-stimulating hormone (FSH) as predictors of ovarian function  David H. Barad, M.D., M.S., Andrea Weghofer,
Egg production predicts a doubling of in vitro fertilization pregnancy rates even within defined age and ovarian reserve categories  Melissa C. Yih, M.D.,
Cem Fiçicioǧlu, M. D. , Tayfun Kutlu, M. D. , Elif Baglam, M. D
Microdose gonadotropin-releasing hormone agonist in the absence of exogenous gonadotropins is not sufficient to induce multiple follicle development 
A novel “delayed start” protocol with gonadotropin-releasing hormone antagonist improves outcomes in poor responders  Hakan Cakmak, M.D., Nam D. Tran,
Randomized, controlled pilot trial of natural versus hormone replacement therapy cycles in frozen embryo replacement in vitro fertilization  Ginny Mounce,
Ovarian hyperstimulation syndrome prevention by gonadotropin-releasing hormone agonist triggering of final oocyte maturation in a gonadotropin-releasing.
Oocyte retrieval timing based on spontaneous luteinizing hormone surge during natural cycle in vitro fertilization treatment  Daniel Bodri, M.D., M.Sc.,
Day-5 inhibin B serum concentrations and antral follicle count as predictors of ovarian response and live birth in assisted reproduction cycles stimulated.
Presentation transcript:

Microdose flare protocol with interrupted follicle stimulating hormone and added androgen for poor responders—an observational pilot study  Frederic Mitri, M.D., Lucy Ann Behan, M.D., Courtney A. Murphy, B.H.Sc., Anat Hershko-Klement, M.D., Robert F. Casper, M.D., Yaakov Bentov, M.D., M.Sc.  Fertility and Sterility  Volume 105, Issue 1, Pages 100-105.e6 (January 2016) DOI: 10.1016/j.fertnstert.2015.09.038 Copyright © 2016 American Society for Reproductive Medicine Terms and Conditions

Figure 1 Combined data for study and control groups. Error bars indicate ±SEM. Fertility and Sterility 2016 105, 100-105.e6DOI: (10.1016/j.fertnstert.2015.09.038) Copyright © 2016 American Society for Reproductive Medicine Terms and Conditions

Figure 2 Change in serum estradiol levels during the gonadotropin withdrawal for all 13 patients. Each line represents a patient. Fertility and Sterility 2016 105, 100-105.e6DOI: (10.1016/j.fertnstert.2015.09.038) Copyright © 2016 American Society for Reproductive Medicine Terms and Conditions

Supplemental Figure 1 Combined figures and tables portraying serum E2 and FSH and follicle size in relation to cycle day number. Interrupted intervals are highlighted in blue on both graphs and tables. The first highlighted day indicates gonadotropin withdrawal and the subsequent highlighted day indicates gonadotropin resumption. Only follicles >10 mm and baseline antral follicle (AF) counts are represented. Fertility and Sterility 2016 105, 100-105.e6DOI: (10.1016/j.fertnstert.2015.09.038) Copyright © 2016 American Society for Reproductive Medicine Terms and Conditions

Supplemental Figure 1 Combined figures and tables portraying serum E2 and FSH and follicle size in relation to cycle day number. Interrupted intervals are highlighted in blue on both graphs and tables. The first highlighted day indicates gonadotropin withdrawal and the subsequent highlighted day indicates gonadotropin resumption. Only follicles >10 mm and baseline antral follicle (AF) counts are represented. Fertility and Sterility 2016 105, 100-105.e6DOI: (10.1016/j.fertnstert.2015.09.038) Copyright © 2016 American Society for Reproductive Medicine Terms and Conditions

Supplemental Figure 1 Combined figures and tables portraying serum E2 and FSH and follicle size in relation to cycle day number. Interrupted intervals are highlighted in blue on both graphs and tables. The first highlighted day indicates gonadotropin withdrawal and the subsequent highlighted day indicates gonadotropin resumption. Only follicles >10 mm and baseline antral follicle (AF) counts are represented. Fertility and Sterility 2016 105, 100-105.e6DOI: (10.1016/j.fertnstert.2015.09.038) Copyright © 2016 American Society for Reproductive Medicine Terms and Conditions

Supplemental Figure 2 Baseline antral follicle count plotted against the total number of oocytes retrieved for all 13 patients. Each dot represents a patient. Fertility and Sterility 2016 105, 100-105.e6DOI: (10.1016/j.fertnstert.2015.09.038) Copyright © 2016 American Society for Reproductive Medicine Terms and Conditions

Supplemental Figure 3 Maximum serum FSH levels (pmol/L) before and after gonadotropin withdrawal and resumption for all 13 patients. Fertility and Sterility 2016 105, 100-105.e6DOI: (10.1016/j.fertnstert.2015.09.038) Copyright © 2016 American Society for Reproductive Medicine Terms and Conditions

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.